A Drug for Hunger Offers Clues to Obesity's Complexity
Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction.
The irony stung: When Dean was born, he was so weak and floppy he survived only with feeding tubes because he couldn't suck or swallow. He was diagnosed as a baby with Prader-Willi syndrome — a rare disorder sparked by a genetic abnormality. He continued to be disinterested in food for years. But doctors warned that as Dean grew, his hunger would eventually become so uncontrollable he could gain dangerous amounts of weight and even eat until his stomach ruptured.
'It's crazy,' said Foley Shenk, who lives in Richmond, Virginia. 'All of a sudden, they flip.'
Prader-Willi syndrome affects up to 20,000 people in the US. The most striking symptom is its most life-threatening: An insatiable hunger known as hyperphagia that prompts caregivers to padlock cupboards and fridges, chain garbage cans, and install cameras. Until recently, the only treatment was growth hormone therapy to help patients stay leaner and grow taller, but it didn't address appetite.
In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the biology of extreme appetite and binge eating. This breakthrough for these patients comes as other drugs are revolutionizing how doctors treat obesity, which affects more than 40% of American adults. GLP-1 agonist medications Ozempic, Wegovy, and others also are delivering dramatic results for millions.
But what's becoming clear is that obesity isn't one disease — it's many, said Jack Yanovski, a senior obesity researcher at the National Institutes of Health, who co-authored some of the Vykat XR studies. Researchers are learning that obesity's drivers can be environmental, familial, or genetic. 'It only makes sense that it's complex to treat,' Yanovski said.
Obesity medicine is likely heading the way of treatments for high blood pressure or diabetes, with three to five effective options for different types of patients. For example, up to 15% of patients in the GLP-1 trials didn't respond to those drugs, and at least one study found the medications didn't significantly help Prader-Willi patients.
Yet, researchers say, efforts to understand how to treat obesity's many causes and pathways are now in question as the Trump administration is dismantling the nation's infrastructure for medical discovery.
While Health and Human Services Secretary Robert F. Kennedy, Jr, promotes a 'Make America Healthy Again' agenda centered on diet and lifestyle, federal funding for health research is being slashed, including some grants that support the study of obesity. University labs face cuts, FDA staffers are being laid off en masse, and rare disease researchers fear the ripple effects across all medical advances. Even with biotech partnerships — such as the work that led to Vykat XR — progress depends on NIH-funded labs and university researchers.
'That whole thing is likely to get disrupted now,' said Theresa Strong, research director for the Foundation for Prader-Willi Research.
HHS spokesperson Andrew Nixon said in a statement that no NIH awards for Prader-Willi syndrome research have been cut. 'We remain committed to supporting critical research into rare diseases and genetic conditions,' he said.
But Strong said that already some of the contacts at the FDA she'd spent nearly 15 years educating about the disorder have left the agency. She's heard that some research groups are considering moving their labs to Europe.
Early progress in hunger and obesity research is transforming the life of Dean Shenk. During the trial for Vykat XR, his anxiety about food eased so much that his parents began leaving cupboards unlocked.
Jennifer Miller, a pediatric endocrinologist at the University of Florida who co-led the Vykat XR trials, treats around 600 Prader-Willi patients, including Dean. She said the impact she's seen is life-changing. Since the drug trial started in 2018, some of her adult patients have begun living independently, getting into college, and starting jobs — milestones that once felt impossible. 'It opens up their world in so many ways.'
Over 26 years in practice, she's also seen just how severely the disease hurts patients. One patient ate a 4-lb bag of dehydrated potato flakes; another ingested all 10 frozen pizzas from a Costco pack; some ate pet food. Others have climbed out of windows, dived into dumpsters, even died after being hit by a car while running away from home in search of food.
Low muscle tone, developmental delays, cognitive disabilities, and behavioral challenges are also common features of the disorder.
Dean attends a special education program, his mother said. He also has narcolepsy and cataplexy — a sudden loss of muscle control triggered by strong emotions. His once-regular meltdowns and skin-picking, which led to deep, infected lesions, were tied to anxiety over his obsessive, almost painful urge to eat.
In the trial, though, his hyperphagia was under control, according to Miller and Dean's mother. His lean muscle mass quadrupled, his body fat went down, and his bone mineral density increased. Even the skin-picking stopped, Foley Shenk said.
Vykat XR is not a cure for the disease. Instead, it calms overactive neurons in the hypothalamus that release neuropeptide Y — one of the body's strongest hunger signals. 'In most people, if you stop secreting NPY, hunger goes away,' said Anish Bhatnagar, CEO of Soleno Therapeutics, which makes the medication, the company's first drug. 'In Prader-Willi, that off switch doesn't exist. It's literally your brain telling you, 'You're starving,' as you eat.'
GLP-1 drugs, by contrast, mimic a gut hormone that helps people feel full by slowing digestion and signaling satiety to the brain.
Vykat XR's possible side effects include high blood sugar, increased hair growth, and fluid retention or swelling, but those are trade-offs that many patients are willing to make to get some relief from the most devastating symptom of the condition.
Still, the drug's average price of $466,200 a year is staggering even for rare-disease treatments. Soleno said in a statement it expects broad coverage from both private and public insurers and that the copayments will be 'minimal.' Until more insurers start reimbursing the cost, the company is providing the drug free of charge to trial participants.
Soleno's stock soared 40% after the FDA nod and has held fairly steady since, with the company valued at nearly $4 billion as of early June.
While Vykat XR may be limited in whom it can help with appetite control, obesity researchers are hoping the research behind it may help them decode the complexity of hunger and identify other treatment options.
'Understanding how more targeted therapies work in rare genetic obesity helps us better understand the brain pathways behind appetite,' said Jesse Richards, an internal medicine physician and the director of obesity medicine at the University of Oklahoma-Tulsa's School of Community Medicine.
That future may already be taking shape. For Prader-Willi, two other notable phase 3 clinical trials are underway, led by Acadia Pharmaceuticals and Aardvark Therapeutics, each targeting different pathways. Meanwhile, hundreds of trials for general obesity are currently recruiting despite the uncertainties in US medical research funding.
That brings more hope to patients like Dean. Nearly 6 years after starting treatment, the now-16-year-old is a calmer, happier kid, his mom said. He's more social, has friends, and can focus better in school. With the impulse to overeat no longer dominating his every thought, he has space for other interests — Star Wars, American Ninja Warrior, and a healthy appreciation for avocados among them.
'Before the drug, it just felt like a dead end. My child was miserable,' Foley Shenk said. 'Now, we have our son back.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
41 minutes ago
- CNN
I tossed my expensive makeup to get rid of my acne. Here are the noncomedogenic products I use now
Noncomedogenic makeup quick picks Skin tint: Make Beauty Diffusion Dew Radiant Skin Tint Highlighter: Haus Labs by Lady Gaga Bio-Radiant Gel-Powder Illuminating Highlighter Setting powder: RMS Beauty Un Powder Brow gel: Kimiko The Brow Sensei In my mid-twenties, I was hit with a wave of stubborn cystic acne that covered my face seemingly overnight. After trying countless products, the real shift came when I switched to Clearstem — a noncomedogenic (aka non-pore-clogging) skin care line designed to tackle breakouts and wrinkles. While my skin finally started to clear, I still couldn't shake some breakouts — until I realized my makeup products might be the culprit. It turns out even beauty products can clog pores! So, I did something dramatic and expensive: I cross-checked my makeup ingredients using Clearstem's Pore-Clogging Ingredients Checker, tossed everything I owned and started fresh. After lots of trial and error, I finally found the best noncomedogenic makeup, from Charlotte Tilbury to Rare Beauty and more. Merit Great Skin Instant Glow Serum There's a reason this serum has 'glow' in its name. Worn with makeup or by itself, it leaves my skin looking lit from within, thanks to ingredients like hyaluronic acid and niacinamide. Make Beauty Diffusion Dew Radiant Skin Tint This lightweight foundation features skin-mimicking pigments that blur, smooth and brighten. It's sheer yet buildable, making it perfect for a second-skin or full-coverage glam look. Rare Beauty Warm Wishes Effortless Cream Bronzer Stick You may have seen this bronzing stick all over TikTok, and I can confirm it's worth the hype! It glides on effortlessly and melts into my skin for the most natural, sun-kissed glow. Huda Beauty Easy Blur Primer My colleague, associate testing writer Carolina Gazal, also has acne-prone skin and said she's "extremely careful when it comes to [her] makeup choices." She swears by this silicone-free, noncomedogenic primer. "I love this jelly-like, antioxidant-rich formula that blurs pores instantly," she said. "It's also made with glycerin to control oil, making foundation last longer without that dreaded T-zone shine." Haus Labs by Lady Gaga Bio-Radiant Gel-Powder Illuminating Highlighter Leave it to Lady Gaga to create the best highlighter on the market. This pressed-powder formula is packed with glow-boosting ingredients that make my cheekbones truly shine. Priia Lip Butter Balm Summer Fridays, who? This under-$10, buildable vegan lip butter balm is infused with acne-safe botanicals and leaves my lips looking and feeling hydrated and plump. Charlotte Tilbury Airbrush Flawless Setting Spray Good news: Not all Charlotte Tilbury products include pore-clogging ingredients! That includes the brand's ultra-viral setting spray, which locks in makeup all day long. RMS Beauty Un Powder Formulated with silica, this nontoxic setting powder instantly absorbs oil and minimizes the appearance of pores. Best of all, it's never drying, so it's great for all skin types. Kimiko The Brow Sensei Not only does this clear gel style and keep my brows in place but it's made with growth- and hair-enhancing peptides. I swear, my brows have never looked fuller! Olio E Osso Tinted Balm Associate deals editor Elena Matarazzo said she stocks up on these sensitive skin-friendly multisticks for friends and family. They're made with natural oils and waxes but none that are flagged as pore cloggers. "The clear one is great for chapped hands, cheeks and other areas that need a bit of hydration, while the tinted version doubles as a lip balm and blush," she said. Know how pore cloggers work Your first step to putting your best face forward? Staying up to date on what might actually be clogging your pores in the first place. Danielle Gronich, co-founder and CEO of Clearstem, suggests 'thinking of pore cloggers as ingredients that create a sticky, occlusive film on your skin. This film traps dead skin cells, oil and bacteria inside your pores, leading to congestion, blackheads, whiteheads and, ultimately, pimples.' Look for the right products When sourcing the right noncomedogenic products for your skin, it helps to know which ingredients are worth prioritizing. 'We want ingredients that are both skin-loving and noncomedogenic,' Gronich said. 'Look for hyaluronic acid, niacinamide, zinc oxide, green tea extract and kaolin clay.' While sourcing the best noncomedogenic ingredients is a solid place to start, it's only part of the equation. Consider steering clear of what our experts deem pore-clogging ingredients as well. 'Some ingredients that may be considered pore clogging include cocoa butter, isopropyl myristate, coconut oil and ethylhexyl palmitate,' Dr. Marisa Garshick, a board-certified dermatologist at MDCS Dermatology, said. Learn more about your own skin What works for one person's skin might yield a breakout in another, so it helps to track patterns in your own skin or book a consultation with a skin specialist or dermatologist to gain tangible insights into what might fare best for you. 'Just because ingredients may be pore clogging, it doesn't mean everyone who uses them will necessarily experience breakouts,' Garshick said. The following FAQs have been answered by Dr. Marisa Garshick and Clearstem co-founder and CEO Danielle Gronich. What is noncomedogenic makeup? What is noncomedogenic makeup? 'Noncomedogenic makeup is formulated without the heavy, occlusive ingredients that are known to clog pores,' Gronich said. 'It allows your skin to 'breathe' and function properly, helping minimize the risk of breakouts. It's designed to be gentler and more compatible with acne-prone skin.' However, Gronich also said that just because 'noncomedogenic' is on the label, that doesn't guarantee that a product is truly acne-safe. 'The term isn't tightly regulated, so some products may still contain ingredients that can clog pores — especially for those with sensitive or acne-prone skin,' she said. 'Always check the full ingredient list for pore cloggers. What works for one person may trigger breakouts in another, so being your own skin detective is key!' How do I check for pore-clogging ingredients in makeup? How do I check for pore-clogging ingredients in makeup? 'I always tell people to check the ingredient list,' Gronich said. 'We created an online resource, Clearstem's Pore-Clogging Ingredients Checker, where you can input your products and see if they have pore cloggers.' In addition to checking new products you want to try, Garshick said to check for pore-clogging ingredients every time you repurchase a product too. 'Brands can change their formulations for a variety of reasons at any time, so it's always best to double-check,' she said. Besides impacting acne-prone skin, how else do pore-clogging ingredients negatively affect skin? Besides impacting acne-prone skin, how else do pore-clogging ingredients negatively affect skin? 'In some cases, pore-clogging ingredients may lead to milia formation, even in those who are not acne-prone,' Garshick said. 'Some ingredients may also be irritating on the skin, which should be considered for those with sensitive skin.' The dermatologist also said that pore-clogging ingredients may even create a barrier on the skin, which can make other products less effective since they won't penetrate as well. For this article, we consulted the following experts to gain their professional insights. Dr. Marisa Garshick, board-certified dermatologist at MDCS Dermatology in New York and New Jersey Danielle Gronich, co-founder and CEO of Clearstem Here at CNN Underscored, we make it our job to stay up to date on all the latest products, but we don't just find them; we also rigorously test products from hundreds of brands to make sure every product we recommend is worthy of your money. In addition to hands-on testing many of the products we feature, we also consult top experts to understand what qualities, benefits and possible downsides each item offers. We also seek out important considerations and advice from our experts to help give you the information you need to make smarter shopping decisions. For this article, our director of social, Stephanie Griffin, shared her favorite noncomedogenic makeup and tips for finding products that won't clog your pores.
Yahoo
an hour ago
- Yahoo
With 59% institutional ownership, eHealth, Inc. (NASDAQ:EHTH) is a favorite amongst the big guns
Institutions' substantial holdings in eHealth implies that they have significant influence over the company's share price The top 17 shareholders own 51% of the company Insiders have been buying lately AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Every investor in eHealth, Inc. (NASDAQ:EHTH) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 59% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. In the chart below, we zoom in on the different ownership groups of eHealth. Check out our latest analysis for eHealth Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that eHealth does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of eHealth, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 14% of eHealth shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that 8 Knots Management, LLC is the largest shareholder with 8.1% of shares outstanding. For context, the second largest shareholder holds about 5.6% of the shares outstanding, followed by an ownership of 4.4% by the third-largest shareholder. In addition, we found that Francis Soistman, the CEO has 2.3% of the shares allocated to their name. After doing some more digging, we found that the top 17 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We can report that insiders do own shares in eHealth, Inc.. As individuals, the insiders collectively own US$7.4m worth of the US$123m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying. With a 21% ownership, the general public, mostly comprising of individual investors, have some degree of sway over eHealth. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. It's always worth thinking about the different groups who own shares in a company. But to understand eHealth better, we need to consider many other factors. Take risks for example - eHealth has 2 warning signs we think you should be aware of. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Media Alert: House of Good Presents the Well+Good Shop
Self-Care Studio to Help Shoppers Find Their New Self-Care Regimen VENICE, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Join Well+Good IRL at House of Good to shop feel-good products across home, beauty, fitness, tech, and more all month. WHAT: Escape the hustle of Abbot Kinney and enter into a feel-good emporium—curated with Well+Good editor recommendations. June's Self-Care Studio at the Well+Good Shop is where all forms of self-care converge, blending movement, beauty, and recovery into one immersive, shoppable space. All month long, visit to find the best wellness buys and test & shop your favorite brands, including: Active&Fit Blueair California Walnuts ThirdLove Auratherapy Aviron Canopy Cariuma Hyperice KORRES Lifepro Fitness NordicTrack NOYZ HigherDOSE Homecourt Public Goods Wildling WHO: This event is free and open to the public. WHEN: June 20 - 29, 2025, open Thursdays - Sundays, 12 p.m. - 7 p.m. Visit for aura photography presented by Auratherapy throughout the month. Additional special activations include: Friday, June 20: Greek Yogurt Sampling Bar presented by KORRES Saturday, June 21: Breathwork Session with The Breathing Room Saturday, June 21: Gua Sha Demonstration with Wildling Saturday, June 28: Meditation Session with Grace Whitlock Saturday, June 28 and Sunday, June 29: Trail Mix Sampling Bar presented by California Walnuts. WHERE: House of Good: 1511 Abbot Kinney Blvd, Los Angeles, CA 90291 To learn more, visit About Well+GoodWell+Good is a health and wellness media brand, known for its journalistic integrity, expert-led editorial, and ahead-of-the-curve trend-spotting. Founded in 2010, Well+Good delivers inclusive content that makes the path to feeling good feel good—for everyone. By amplifying different perspectives, experiences, and stories, Well+Good helps people decide on the lifestyle changes that work for them. The female-founded company has been recognized as a vertical media leader and creates high-quality consumer events at House of Good, its real-life home in Venice, CA. About World of Good BrandsWorld of Good Brands is a leader in experiential media and commerce operating premium lifestyle brands including Well+Good, OnlyInYourState, and House of Good. World of Good Brands creates consumer experiences that blend physical and virtual – allowing audiences to access them from wherever they are, and taking a piece of them wherever they go. While traditional media companies broadcast, World of Good Brands narrowcasts: the brands close the aperture on the communities, conversations, and connections that bring color and meaning to our worlds. The World of Good Brands niche digital properties have deep connections with their consumers, and can be amplified through a collection of 50+ digital properties representing consumers across lifestyles and life stages: offering premium reach and powerful audience extension opportunities for partners. Formerly known as Leaf Group Media, World of Good Brands is a Graham Holdings Company (NYSE: GHC) subsidiary. To learn more, visit Media ContactSusan TurnerSenior Director, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
